-
Decreasing Progression, Increasing Function
Chairman and CSO Dr. Karl Johe and Principal Investigator Dr. Eva Feldman are quoted in this article on Neuralstem’s NSI-566/ALS program that looks ahead to Phase III, overviews Phase II and explores Phase I findings, following Dr. Feldman’s presentation of data at the 2013 Canadian Neurological Sciences Federation Congress.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.